Skip to Content
Merck
  • MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure.

MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure.

European journal of heart failure (2015-03-06)
Chris J Watson, Shashi K Gupta, Eoin O'Connell, Sabrina Thum, Nadezhda Glezeva, Jasmin Fendrich, Joe Gallagher, Mark Ledwidge, Lea Grote-Levi, Kenneth McDonald, Thomas Thum
ABSTRACT

Differentiation of heart failure with reduced (HFrEF) or preserved (HFpEF) ejection fraction independent of echocardiography is challenging in the community. Diagnostic strategies based on monitoring circulating microRNA (miRNA) levels may prove to be of clinical value in the near future. The aim of this study was to identify a novel miRNA signature that could be a useful HF diagnostic tool and provide valuable clinical information on whether a patient has HFrEF or HFpEF. MiRNA biomarker discovery was carried out on three patient cohorts, no heart failure (no-HF), HFrEF, and HFpEF, using Taqman miRNA arrays. The top five miRNA candidates were selected based on differential expression in HFpEF and HFrEF (miR-30c, -146a, -221, -328, and -375), and their expression levels were also different between HF and no-HF. These selected miRNAs were further verified and validated in an independent cohort consisting of 225 patients. The discriminative value of BNP as a HF diagnostic could be improved by use in combination with any of the miRNA candidates alone or in a panel. Combinations of two or more miRNA candidates with BNP had the ability to improve significantly predictive models to distinguish HFpEF from HFrEF compared with using BNP alone (area under the receiver operating characteristic curve >0.82). This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dibutyl phthalate, SAJ special grade, ≥98.0%
Supelco
Dibutyl phthalate, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
(+)-Biotin 4-nitrophenyl ester, 98%
Supelco
Dibutyl phthalate, PESTANAL®, analytical standard
Sigma-Aldrich
Dibutyl phthalate, 99%
Dibutyl phthalate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, JIS special grade, ≥99.0%
Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, SAJ first grade, ≥98.0
Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, BioXtra, ≥99.0% (T)
Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, tested according to Ph. Eur.
Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, puriss. p.a., crystallized, ≥99.0% (T)
Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, meets analytical specification of Ph. Eur., BP, E339, 98.5-102.5% (T)